Clinical Trials Sponsored by Ali Yurtseven

Total 4678 results

Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

Renal Insufficiency | End Stage Renal Disease

United States
Eli Lilly and Company

Terminated

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Germany, Australia, Italy, Israel, Poland, Japan, Argentina, Hungary, Taiwan, United Kingdom, Mexico, Czechia, Russian Federation
Eli Lilly and Company

Completed

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Germany
Eli Lilly and Company

Completed

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Advanced Cancer

United States
Kirsehir Ahi Evran Universitesi

Completed

The Efficacy of Kinesiotaping on Pain, Edema and Functionality After Total Knee Arthroplasty

Pain | Edema | Knee Arthroplasty

Turkey
Eli Lilly and Company

Withdrawn

A Study of LY3526318 in Healthy Male Japanese Participants

Healthy

Japan
Eli Lilly and Company

Completed

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Completed

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

A Study of LY3502970 in Healthy Overweight and Obese Participants

Healthy | Obese

United States
Eli Lilly and Company

Completed

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Neoplasm Metastasis

United States
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Alzheimer Disease

United States, Canada
Eli Lilly and Company

Completed

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-BASIS)

Juvenile Idiopathic Arthritis

Spain, India, Israel, Japan, Australia, Belgium, Turkey, Mexico, Italy, Germany, Czechia, United Kingdom, China, Russian Federation, Poland, Brazil, France, Austria, Argentina, Denmark
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease (SERENITY)

Crohn's Disease

United States, Belgium, Netherlands, Australia, Hungary, United Kingdom, Czechia, Poland, Switzerland, Japan, Romania, Ukraine, Russian Federation, Canada
Eli Lilly and Company

Completed

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Completed

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Migraine

Spain, Italy, China, United States, India, Switzerland, Germany, United Kingdom, Czechia, Austria, Belgium, Netherlands, France, Russian Federation, Denmark, Mexico, Hungary
ALK-Abelló A/S

Terminated

A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber (QUEST)

Allergic Rhinoconjunctivitis

Austria, China
Eli Lilly and Company

Completed

A Study of LY3473329 in Healthy Japanese Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China, Malaysia, Thailand, Philippines
Kirsehir Ahi Evran Universitesi

Completed

The Relationship Between Trunk Muscle Endurance and Physical Activity, Low Back Pain and Fatigue in Young Adults

Healthy

Turkey
Eli Lilly and Company

Completed

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (ANNOUNCE 2)

Soft Tissue Sarcoma

United States, France, Spain, Australia, Germany, United Kingdom, Israel, Hungary, Italy, Poland
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes (SURPASS J-mono)

Type 2 Diabetes

Japan
Eli Lilly and Company

Completed

A Study of Two Formulations of Ixekizumab in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3023414 in Participants With Advanced Cancer

Non-Hodgkin's Lymphoma | Metastatic Cancer | Malignant Mesothelioma | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Advanced Cancer

United States, Puerto Rico, Italy
Kirsehir Ahi Evran Universitesi

Completed

The Effect of the Education Program Based on the PRECEDE-PROCEED Model on the Smoking Behaviors of Nursing Students

Smoking Cessation

Turkey
Eli Lilly and Company

Completed

A Study of LY3871801 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Malignant Solid Tumor

United States
Eli Lilly and Company

Completed

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China, Taiwan, Thailand, Korea, Republic of, Hong Kong
Eli Lilly and Company

Completed

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

Healthy | Type 2 Diabetes

Germany
Eli Lilly and Company

Completed

A Study of LY3473329 in Healthy Participants

Healthy

Netherlands
Eli Lilly and Company

Completed

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Breast Cancer

United States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
Eli Lilly and Company

Terminated

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States, Australia
Eli Lilly and Company

Completed

A Study of LY3493269 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Hypertension, Pulmonary

Spain, Poland, Belgium, Germany, Netherlands, United States, Japan, Brazil, Israel, Italy, Austria, Turkey, France, Mexico
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (SURPASS-1)

Type 2 Diabetes Mellitus

United States, Japan, India, Puerto Rico, Mexico
Eli Lilly and Company

Completed

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

Advanced Cancer

Japan
Eli Lilly and Company

Withdrawn

A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes

Type 1 Diabetes | Type 2 Diabetes

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Germany, Italy, Spain, United States, Hungary, Russian Federation, Poland, Belgium, Netherlands, France, Czechia, Mexico, Argentina, Canada, Denmark, Finland, Israel, Japan, Puerto Rico, United Kingdom
Eli Lilly and Company

Withdrawn

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Eli Lilly and Company

Terminated

A Study of LY3127804 in Participants With COVID-19

COVID-19 | Pneumonia

United States
Eli Lilly and Company

Completed

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Small Cell Lung Cancer

France, Belgium, Spain, United States, Korea, Republic of, Japan, United Kingdom, Turkey
Eli Lilly and Company

Completed

A Study of LY3305677 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Eli Lilly and Company

Completed

A Study of LY3502970 in Healthy Male Participants

Healthy

United Kingdom
ALK-Abelló A/S

Completed

Impact of AIT on Allergic Rhinitis and Asthma

Allergy | Respiratory Disease

Denmark
Eli Lilly and Company

Completed

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Dyslipidemias

United States
Eli Lilly and Company

Withdrawn

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)

Ulcerative Colitis
Eli Lilly and Company

Completed

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

Alzheimer Disease | Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Neoplasm

Japan
Eli Lilly and Company

Completed

A Study of LY3461767 in Healthy Participants

Healthy

United States, Singapore

Clinical Trials Sponsored by Ali Yurtseven

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations